2. Apoptosis Pathways as Mediators of Pain Formation
2.1. Apoptosis Cell Signaling Pathways
The homeostasis of a multicellular organism depends on cell turnover, as it is related to the capacity to maintain the equilibrium between cell proliferation and death
[25][26].
Physiological cell death occurs primarily through an evolutionary and conserved form of cellular suicide, called apoptosis (from the Greek word for decay, as with leaf fall, for example), in response to a series of intrinsic and extrinsic stimuli
[25][26]. It was discovered in 1952. However, in 1972, the Australian pathologist John FR Kerr and the Scots Andrew H. Wylie and Alistair R. Currie showed the importance of this cell death process in developing an adult organism
[25]. Unlike the other type of death, cell necrosis, in which the cell is a passive victim, cell apoptosis is an active form of death, in which the cell expends energy to carry out this genetically programmed cellular suicide process. For this reason, it is often called programmed cell death
[25][27].
The induction of apoptosis can be divided into three steps: the inducing agent’s interaction with the cell, the biochemical transduction of the death signal, and the execution by the apoptotic machinery. Different extracellular signals, such as an increase in ROS production
[28] and/or a decrease in antioxidants resulting in oxidative stress, inflammatory mediators such as TNF- α and IL1-β
[29], moderate hyperactivity stimulation of the N-methyl-D-aspartate (NMDA) receptors
[30], and the endoplasmic reticulum stress
[31] could activate signal transduction pathways that converge on a final common pathway leading to the execution phase of cellular apoptosis. At least two pathways are involved, the mitochondria-dependent pathway (intrinsic or mitochondrial pathway), which is mediated by mitochondria and the B-cell lymphoma-2 (BCL-2) family proteins, and the extrinsic or membrane pathway involving external signaling via membrane receptors from the tumor necrosis factor (TNF) family, such as TNF-R1, FAS, TNF-apoptotic inducing ligand receptors 1 and 2 (TRAIL-R1 and 2, or death receptors DR4 and 5
[32], and the low-affinity nerve growth factor (NGF) receptor, p75-NTR
[13][33]. Moreover, the p38MAPK pathway causes the activation of apoptosis in neuronal cells, inducing pain (such as bone cancer pain-related hyperalgesia)
[34].
However, all the pathways culminate in the activation of a series of cysteine proteases, called caspases. The effector caspases, such as caspase 3, cleave a wide variety of protein targets that are responsible for the characteristic changes in apoptotic cells. These include cell shrinkage, nuclear condensation, membrane blebbing, fragmentation into apoptotic bodies, and membrane changes that can lead to phagocytosis of the affected cell
[11][20]. An alternative, proinflammatory form of apoptosis
[27] in macrophages infected with Salmonella or Shigella, termed “pyroptosis”
[35]. Since its discovery, pyroptosis has been observed in the central nervous system
[36] and the cardiovascular system, suggesting that this form of cell death is biologically significant.
[34][35].
The knowledge of this active physiologic mode of cell death has profound implications on our understanding of several diseases. In fact, the deregulation of apoptosis is involved in the development of several diseases, such as cancer
[37], neurodegenerative diseases as Alzheimer’s and Parkinson’s, and autoimmune or rheumatoid arthritis. Recent evidence suggests that apoptosis may be involved in pain, namely neuropathic pain
[30].
The involvement of apoptosis in pain and the clinical relevance of this knowledge in the discovery of new potential biomarkers and therapeutic targets may be useful for the development of more effective and targeted drugs to treat pain.
2.2. Ubiquitin Proteasome Pathway and Apoptosis
Regulatory proteins involved in normal cell proliferation and differentiation are degraded by a proteolytic pathway, which involves lysosomal enzymes, and a non-lysosomal pathway, known as the ubiquitin–proteasome pathway (UPP)
[38].
The UPP encompasses several enzymes, namely the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and a ligase (E3) that catalyzes the binding of ubiquitin to the target protein, the deubiquitinating enzyme (DUB), and proteasomes (namely the 26S proteasome)
[39].
The degradation of proteins by the UPP involves two successive and distinct steps: first, several ubiquitin molecules bind to the target protein to be subsequently degraded in the proteasomes. Some of the regulatory proteins with levels are controlled by this degradative pathway include proteins involved in cell death by apoptosis, namely the BCL2 family proteins such as BAX protein
[38], and the C-terminal fragment of the BID protein the BIDt
[40], and the IAP family and the inhibitor of the NF-kB, IkB
[41][42].
The UPP is relevant in neural development and brain structure and also in maintenance of their functions, and is implicated in synaptic plasticity, formation, and maintenance of memory. Recently, it was found that the dysfunction of this proteasomal degradation pathway leads to changes in cell death by apoptosis in diverse cell types and may be implicated in the pathogenesis of several diseases, either through hypofunction.
One of the most important enzymes is the ubiquitin-conjugating enzyme E2B (Ube2b), also known as RAD6B. Ube2b is a member of the ubiquitin-conjugating enzyme family that has been identified to be vital in neural DNA double-strand DNA breaks (DSBs). Further, the Ube2b modulates the DNMT3a (DNA methyltransferase 3 alpha) ubiquitination degradation and
CaMKK1 (calcium/calmodulin-dependent protein kinase) gene promoter demethylation increasing CaMKK1 level.
Moreover, the nuclear factor-κB (NF-κB) is a key regulator of molecules and pathways important for inflammation and pain
[43][44][45]. NF-κB can exist as homo or heterodimers composed of the Rel family proteins (the p65/p50 subunits in humans) and is bound to the κB inhibitor (IκBα) in the cytoplasm, when in an inactive state. Upon activation by proinflammatory cytokines and growth factors, among others, the IκB kinase (IKK) phosphorylates IκBα, targeting its degradation in the UPP. As a result, IκBα releases the p65/p50 complex, which subsequently translocates to the nucleus and initiates the transcription of several genes, including inflammatory genes such as TNFα, IL-1β, and cyclooxogenase-2 (COX-2) that directly or indirectly influence pain
[43][44][45]. Thus, targeting the NF-kB pathway, namely by inhibiting the IkB degradation in the UPP could be a new therapeutic approach to treating pain
[31][43][44].
2.3. Endoplasmic Reticulum Stress Signalling and Apoptosis
Endoplasmic reticulum (ER) stress causes the activation of caspase signaling pathway-dependent apoptosis in neuronal cells and induces bone cancer pain-related hyperalgesia.
The ER is the cellular organelle in which protein folding, lipid biosynthesis, and calcium storage take place. Many factors can cause an imbalance in the homeostasis of ER function, resulting in ER stress. Such ER stress initiates an evolutionarily conserved signaling cascade called the unfolded protein response (UPR), which is a self-protective signaling pathway. The accumulation of unfolded proteins in the ER can activate the UPR to restore ER function. Besides the increase in ER stress as a self-protective signal transcription pathway after mild injury, the failure of this system to relieve prolonged or excessive ER stress may cause cell apoptosis, and plays an important role in neuropathic pain, specifically in rat models of bone cancer pain
[31].
2.4. Oxidative Stress
When the synthesis of oxidative species is superior to the capacity of the cells to counteract them, there is the occurrence of oxidative stress. The generation of reactive oxygen species (ROS) in mitochondria is a consequence of oxidative phosphorylation related to the respiratory chain
[46]. ROS acts physiologically as signaling molecules, but when produced in abundance has deleterious consequences to DNA, protein, lipids, initiation of inflammatory events, excitotoxicity, and apoptosis
[47].
Mitochondrial dysfunction, the increase in ROS and reactive nitrogen species (RNS), is involved in the pathogenesis of chronic neuropathic pain
[48], leading to the degeneration of primary afferents
[49], and ROS accumulation originates a feed-forward mechanism of nitroxidative lesion that triggers proapoptotic factors
[50][51].
In fact, mitochondrial dysfunction is observed in various neuropathic pain phenotypes, such as chemotherapy-induced neuropathy, diabetic neuropathy, HIV-associated neuropathy, Charcot–Marie–Tooth neuropathy, and trauma-induced painful mononeuropathy
[51].
More recently, it was shown that damage to mitochondria and aberrant mitochondrial transport in peripheral neurons are common features of peripheral neuropathy
[52]. The complex and highly energy-consuming processes of neurotransmission by peripheral neurons are critically dependent on mitochondrial metabolic functions
[53].
2.5. Inflammation
For five decades, apoptosis has been recognized as fundamental for almost all the critical biological processes that occur in multicellular organisms, since embryogenesis and throughout life, to maintain the homeostatic balance of tissues and organs as well as the progression and final resolution of inflammation
[54][55][56].
However, this physiological form of cell death was very early on associated with the absence of an inflammatory reaction by the surrounding tissues. This was initially explained by the preservation of membrane integrity in such a way that cellular content does not come into contact with neighbouring cells
[54][57][58][59][60][61].
Inside, they contain well-preserved organelles and nuclear fragments, which will be prompt digested and removed from tissues by professional phagocytes or non-professional neighboring cells that specifically recognize apoptotic cells
[57][59].
Although initially it was considered that the maintenance of the integrity of the cellular membrane was the only reason why apoptosis did not cause inflammation, it is now known and consensual that the mechanisms involved in the recognition and subsequent phagocytosis and clearance of apoptotic cells will determine whether apoptosis is immunologically “silent” or anti-inflammatory
[60][61][62][63][64][65].
It seems clear that during apoptosis, the inflammatory response could be blocked
[65] Regarding biochemical explanation, the fact that the inflammatory response is absent during apoptosis was initially explained by the exposure of phagocytes to phosphatidylserine after a process of translocation from the inner to the outer leaflet of the cell membrane (
[66] This “eat me” signal that attracts and allows the recognition of apoptotic cells and their subsequent elimination plays a central role in phagocytosis and is one of the hallmarks of apoptosis
[64][67][68].
Caspase activation, changes in mitochondrial membrane potential, and DNA cleavage are also players in apoptosis, as they contribute to disrupt cellular functions and mark cells for a “silent” phagocytic clearance
[69][70].
Due to activation of caspases that cleave membrane channel proteins results in the release of adenosine monophosphate (AMP)
[70].
Then, through the 5′-nucleotidase a phosphate group is removed from the AMP to produce adenosine that binds to the A2a receptors on the surface of phagocytes to generate the anti-inflammatory response
[70].
Currently, other molecules, such as lysophosphatidylcholine, ATP and uridine 5’-triphosphate (UTP), sphingosine-1-phosphate, CX3CL1/fractalkine, thrombospondin-1, monocyte chemoattractant protein-1 (MCP-1), lactoferrin, are also known as effective in the “silent” clearance of apoptotic cells
[71] These molecules act by sending chemotactic signals that attract phagocytes that recognize apoptotic cell-associated molecular patterns (ACAMPs) on the surface of apoptotic cells, therefore contributing to the anti-inflammatory characteristic of apoptosis.
2.6. The p38MAPK Pathway and Apoptosis
Numerous studies have shown that activation of Mitogen-activated protein kinases (MAPK), particularly c-Jun N-terminal kinase (JNK) and p38, contributes to neuropathic pain pathology
[31][72][73][74].
The activation of the p38MAPK signaling pathway plays an essential role in the generation and maintenance of neuropathic pain by regulating transcription, protein synthesis, receptor expression, and inducing apoptosis. The protein kinase A (PKA) is a key protein involved in neuropathic pain signaling, which by activating the p38MAPK intervenes in the apoptosis of spinal cord cell
[34]. Studies have shown that PKA is closely related to inflammatory pain and bone cancer pain
[74] but it is not clear its involvement in neuropathic pain caused by nerve damage. Scholars hypothesized that PKA is involved in neuropathic pain by mediating spinal cord cell apoptosis through p38MAPK pathway activation, which culminates in a decrease in the antiapoptotic protein BCL2 and an increase in the proapoptotic proteins, TNF-alfa, IL1-beta, BAX, Caspase3 and 9 (
Figure 1)
[34]. Further, it has been suggested that the inhibition of either JNK or p38 may represent a potent clinical target for neuropathic pain management
[34][72].
3. Apoptosis and Clinical Implications
3.1. Apoptosis and Neuropathic Pain
Nerve damage due to oxidative stress and mitochondrial dysfunction is a key pathogenic mechanism involved in chemotherapy-induced peripheral neuropathy (CIPN)
[8][10][12][13][14][15][75]. On the other hand, TRP channels allow calcium to penetrate into nerve terminals. This can activate apoptosis mechanisms that result in nerve terminal destruction
[20] in the skin which can cause long-term pain relief
[20]. Further, cisplatin, oxaliplatin, and paclitaxel-induced mitochondrial oxidative stress, inflammation, cold allodynia, and hyperalgesia, through an increase in TRPA1 and TRPV4, leading to Ca
2+ influx through direct channel activation or excessive production of oxidative stress and induction of apoptosis. The pain resulting from this Ca
2+ overload is mediated through substance P (SP) and excitatory amino acid production. This chemotherapy-induced oxidative stress in DRG neurons that contribute to peripheral pain may be prevented with TRPA1 and TRPM8 antagonists such as reduced glutathione (GSH) and selenium
[9][10][14][76][77][78].
2.2. Biomarkers and Circulating Mediators in Pain
Oxidative damage to peripheral neurons can cause damage to the myelin sheath, mitochondrial proteins, and other antioxidant enzymes
[20]. Identification of levels of malondialdehyde, glutathione (GSH), superoxide dismutase (SOD), and activities of mitochondrial enzymes such as citrate synthase and ATP synthase can help monitor the course of peripheral neuropathy and response of neuropathy to the treatment
[20].
2.3. Pain Therapy through Modulating Apoptosis Activities
Only one-third of patients receive pain relief from current analgesics, such as opiates, nonsteroidal anti-inflammatory drugs, local anesthetics, tricyclic antidepressants, and anticonvulsants, including carbamazepine and gabapentin. Therefore, it seems notable that recent developments in understanding the mechanisms that produce pain, either individually or collectively, have disclosed new potential therapeutic targets for developing more effective drugs
[30].
Isoflurane, a general inhalation anesthetic used for the induction and maintenance of general anesthesia, promotes PI3K/AKT activation, upregulates B-cell lymphoma 2 (Bcl-2)-associated X protein Bcl-2 expression levels, and reduces the expression levels of caspase 3 and caspase 8 in myocardial cells. Isoflurane is beneficial for pain attenuation and inhibits apoptosis in myocardial cells via the PI3K/AKT signaling pathway in mice during cardiac surgery
[79].
Paeoniflorin can not only significantly inhibit the activation of ASK1 and simulate the analgesic effect of ASK1 inhibitors, but also significantly inhibit the response of glial cells and neuroinflammation induced by CCI
[80]. Acting in the same pathway, administration of a p38 inhibitor and a JNK inhibitor ameliorates neuropathic pain symptoms in rodent models
[81][82].
Spare nerve injury (SNI) induces a significant increase in PKA expression in the spinal cord, and PKA is involved in neuropathic pain by activating the p38MAPK pathway to mediate spinal cord cell apoptosis
[34].
Tetramethylpyrazine (TMP) attenuated neuropathic pain-associated hyperalgesia and neuronal apoptosis in the spinal dorsal horn, which was demonstrated by a decreased number of TUNEL-positive cells, upregulation in BCL-2 expression, and downregulation in caspase-3 expression in the spinal dorsal horn. These results suggest that TMP is beneficial for treating neuropathic pain by inhibiting apoptosis via the modulation of BCL-2 and caspase-3 proteins
[83].
The crucial role of NF-kB in several pathologies that accompany pain provides evidence that targeting the NF-kB signaling cascade, including UPP, might have beneficial antinociceptive effects
[43][44][45]. Several proteasome inhibitors are already approved to treat hematological neoplasias, such as multiple myeloma
[84]. The generation of new proteasome inhibitors may represent a new pharmacotherapy for inflammatory pain
[39]. Several studies show that UPP inhibitors can prevent inflammatory pain following injury and infection. The proteasome inhibitor MG132 can inhibit the activation of NF-κB, reversing the inflammatory pain
[85].
4. Conclusions
Neuropathic pain is a chronic pain condition caused by primary damage or dysfunction of the nervous system, but the fine molecular mechanisms have not yet been fully elucidated.
Previous studies have indicated that NF-kB, proinflammatory cytokines such as TNF-α, and oxidative stress play an important role in peripheral mediation of neuropathic pain through apoptosis modulation. Further, the degree of DRG neuronal apoptosis has recently been associated with spinal nerve injury via caspase signaling and/or PKA activation through the p38MAPK pathway, generating and maintaining neuropathic pain.
The adoption of measures to prevent and protect mitochondrial function may constitute a promising therapeutic strategy to alleviate or prevent chronic pain conditions
[86] since mitochondria are a primary source of cellular ROS
[75]. Pharmacological interventions aimed at maintaining normal mitochondrial function may be an alternative therapeutic approach to the direct free radical scavengers for the treatment of CIPN
[75]
Medications that can modulate proinflammatory cytokine expression, the NF-kB pathway, and apoptosis, such as TNF-alpha modulators, G-CSF, proteasome inhibitors, and flavonoids, among others, have the potential to treat neuropathic pain
[22]. However, the timing of administration, dose, and indications for neuropathic pain treatment still need to be validated by clinical studies
[22].
Further, the inhibition of apoptosis via the modulation of BCL-2 and caspase-3 is beneficial for the treatment of neuropathic pain
[83].
The involvement of apoptosis in pain and the clinical relevance of this knowledge in the potential discovery of new biomarkers and therapeutic targets can result in the development of more effective and targeted drugs to treat chronic pain, particularly neuropathic pain.